| pubmed-article:8708712 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8708712 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8708712 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:8708712 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
| pubmed-article:8708712 | lifeskim:mentions | umls-concept:C0021734 | lld:lifeskim |
| pubmed-article:8708712 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:8708712 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:8708712 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:8708712 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:8708712 | pubmed:dateCreated | 1996-9-6 | lld:pubmed |
| pubmed-article:8708712 | pubmed:abstractText | Although high-dose interleukin-2 (IL-2) can produce durable remissions in a subset of responding patients with renal cell carcinoma (RCC), this occurs in the setting of significant toxicity. The purpose of this study is to define the maximum-tolerated dosage (MTD) of IL-2 and interferon alfa-2a (IFN alpha-2a) that can be administered chronically on an outpatient basis. | lld:pubmed |
| pubmed-article:8708712 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8708712 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8708712 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8708712 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8708712 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:LongoD LDL | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:SteinR LRL | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:UrbaW JWJ | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:FentonR GRG | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:CreekmoreS... | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:JanikJ EJE | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:SznolMM | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:SmithJ WJW2nd | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:KoppW CWC | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:ConlonK CKC | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:SharfmanWW | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:VanderMolenL... | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:HolmlundJJ | lld:pubmed |
| pubmed-article:8708712 | pubmed:author | pubmed-author:GauseB LBL | lld:pubmed |
| pubmed-article:8708712 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8708712 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:8708712 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8708712 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8708712 | pubmed:pagination | 2234-41 | lld:pubmed |
| pubmed-article:8708712 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:meshHeading | pubmed-meshheading:8708712-... | lld:pubmed |
| pubmed-article:8708712 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8708712 | pubmed:articleTitle | Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. | lld:pubmed |
| pubmed-article:8708712 | pubmed:affiliation | Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, USA. bgause@mail.ncifcrf.gov | lld:pubmed |
| pubmed-article:8708712 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8708712 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8708712 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8708712 | lld:pubmed |
